GCP
AMLX icon

GSA Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

GSA Capital Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$705K Buy
+39,241
New +$607K 0.04% 756
2026
Q1 		– Sell
-36,758
Closed -$444K – 1684
2025
Q4 		$444K Sell
36,758
-15,349
-29% -$208K 0.04% 902
2025
Q3 		$708K Sell
52,107
-118,426
-69% -$1.11M 0.06% 615
2025
Q2 		$1.09M Buy
170,533
+147,448
+639% +$717K 0.08% 401
2025
Q1 		$82K Buy
23,085
+12,446
+117% +$44.3K 0.01% 1520
2024
Q4 		$40K Buy
+10,639
New +$50.1K ﹤0.01% 1541
2024
Q2 		– Sell
-79,652
Closed -$226K – 1596
2024
Q1 		$226K Sell
79,652
-52,525
-40% -$687K 0.02% 1352
2023
Q4 		$1.95M Buy
132,177
+89,742
+211% +$1.38M 0.16% 128
2023
Q3 		$777K Buy
42,435
+28,431
+203% +$601K 0.07% 535
2023
Q2 		$302K Buy
14,004
+5,895
+73% +$159K 0.03% 1046
2023
Q1 		$238K Buy
+8,109
New +$282K 0.02% 1160

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

GSA Capital Partners's AMLX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 39,241 shares worth $705K. The stake represents 0.04% of the portfolio and ranks #756 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in AMLX as recently as Q4 2025.

GSA Capital Partners first reported a position in AMLX in Q1 2023 and has held it in 11 quarters since. The position peaked at $1.95M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • GSA Capital Partners held 39,241 shares of Amylyx Pharmaceuticals worth $705K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new GSA Capital Partners position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #756 holding.
  • GSA Capital Partners first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
  • GSA Capital Partners's Amylyx Pharmaceuticals position peaked at $1.95M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.